alexa Switch To Aflibercept In Diabetic Macular Edema Patients Unresponsive To Anti-VEGF
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

10th International Conference on Clinical & Experimental Ophthalmology
November 21-23, 2016 Dubai, UAE

Filipe Mira
Centro Hospitalar Medio Tejo, Portugal
Posters & Accepted Abstracts: J Clin Exp Ophthalmol
DOI: 10.4172/2155-9570.C1.049
Introduction & Aim: The diabetic macular edema is the leading cause of blindness in working-age patients. The aim of this study was to evaluate the efficacy of aflibercept in patients with diabetic macular edema unresponsive to anti-VEGF. Material & Methods: Retrospective chart review of patients with diabetic macular edema unresponsive to anti-VEGF switched to aflibercept with 3 months of follow up. All patients have had a minimum of 3 injections of anti-VEGF before switch. Changes in best correct visual acuity, central retinal thickness and frequency of injection were analyzed. Additionally, the percentage of subjects who had vision ≥ 20/40 (logMAR 0.3) and ≤ 20/200 (logMAR +1) were evaluated. Results: A total of 32 eyes from 26 diabetic patients were included. The mean age was 65±10 years old and the majority was female (53%). The mean number of previous anti-VEGF injections was 5.03±2.19 and the mean number of aflibercept injections at the end of the study was 2.00±0.00. The central retinal thickness at baseline was 501.47±150.51 μm and 367.97±124.61 μm at 3 months follow up (P=0.000). The best correct visual acuity at baseline was 0.71±0.36 logMAR and 0.65±0.33 logMAR at the end of the follow up (P=0.037). At baseline 12.5% of patients had vision 20/40 or better comparing with 25% at 3rd month follow up. At baseline 28.13% of patients had vision 20/200 or inferior comparing with 15.63% at the end of the follow up. Approximately 63% of patients improved vision, 18.75% maintained vision and 18.75% loss vision at the end of the study. Further analysis did not show any correlation between central retinal thicknesses, best correct visual acuity and the number of prior anti-VEGF treatments. Conclusions: Patients with diabetic macular edema unresponsive to previous multiple anti-VEGF injections demonstrate a significant anatomical and functional improvement with switch to aflibercept.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version